Skip to main content
Erschienen in: Zeitschrift für Gerontologie und Geriatrie 2/2014

01.02.2014 | Beiträge zum Themenschwerpunkt

Algorithm for anticoagulation management in geriatric hip fracture patients—Surgeons save Blood

verfasst von: M.A. Wendl-Soeldner, C.W.I. Moll, C. Kammerlander, M. Gosch, T. Roth, MD

Erschienen in: Zeitschrift für Gerontologie und Geriatrie | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

During the past decades, the number of hip fractures has been increasing steadily. Perioperative thromboprophylaxis has become a routine aspect in the care of geriatric hip fracture patients. In addition, a large proportion of these patients are already anticoagulated because of internistic comorbidities before they sustained the hip fracture. Although the management of preexisting anticoagulation in both orthopedic elective and emergency procedures is well reported, proximal femoral fractures are classified as “acute” and therefore represent neither of these two categories. In this study, we review the different options of handling preexisting anticoagulation and antiaggregation as well as perioperative thromboprophylaxis. The Innsbruck Algorithm for the management of anticoagulation in geriatric hip fracture patients suggests how perioperative bleeding risk can be minimized, while still addressing the underlying disease.
Literatur
1.
Zurück zum Zitat Hopkins RB et al (2012) Estimation of the lifetime risk of hip fracture for women and men in Canada. Osteoporos Int 23:921–927PubMedCrossRef Hopkins RB et al (2012) Estimation of the lifetime risk of hip fracture for women and men in Canada. Osteoporos Int 23:921–927PubMedCrossRef
2.
Zurück zum Zitat Nguyen ND, Ahlborg HG, Center JR et al (2007) Residual lifetime risk of fractures in women and men. J Bone Miner Res 22:781–788PubMedCrossRef Nguyen ND, Ahlborg HG, Center JR et al (2007) Residual lifetime risk of fractures in women and men. J Bone Miner Res 22:781–788PubMedCrossRef
3.
Zurück zum Zitat Falck-Ytter Y et al (2012) Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST 141:e278S–e325SPubMedCentralPubMedCrossRef Falck-Ytter Y et al (2012) Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST 141:e278S–e325SPubMedCentralPubMedCrossRef
4.
Zurück zum Zitat Bucking B, Bliemel C, Waschnick L et al (2013) Anticoagulation medication for proximal femoral fractures: prospective validation study of new institutional guidelines. Unfallchirurg116:909–915 Bucking B, Bliemel C, Waschnick L et al (2013) Anticoagulation medication for proximal femoral fractures: prospective validation study of new institutional guidelines. Unfallchirurg116:909–915
5.
Zurück zum Zitat Liem IS, Kammerlander C, Suhm N et al (2013) Identifying a standard set of outcome parameters for the evaluation of orthogeriatric co-management for hip fractures. Injury 44:1403–1412PubMedCrossRef Liem IS, Kammerlander C, Suhm N et al (2013) Identifying a standard set of outcome parameters for the evaluation of orthogeriatric co-management for hip fractures. Injury 44:1403–1412PubMedCrossRef
6.
Zurück zum Zitat Leung F, Lau TW, Kwan K et al (2010) Does timing of surgery matter in fragility hip fractures? Osteoporos Int 21:S529–S534PubMedCrossRef Leung F, Lau TW, Kwan K et al (2010) Does timing of surgery matter in fragility hip fractures? Osteoporos Int 21:S529–S534PubMedCrossRef
7.
Zurück zum Zitat Khan SK, Kalra S, Khanna A et al (2009) Timing of surgery for hip fractures: a systematic review of 52 published studies involving 291,413 patients. Injury 40:692–697PubMedCrossRef Khan SK, Kalra S, Khanna A et al (2009) Timing of surgery for hip fractures: a systematic review of 52 published studies involving 291,413 patients. Injury 40:692–697PubMedCrossRef
9.
Zurück zum Zitat Luger TJ et al (2010) Neuroaxial versus general anaesthesia in geriatric patients for hip fracture surgery: does it matter? Osteoporos Int 21:555–572CrossRef Luger TJ et al (2010) Neuroaxial versus general anaesthesia in geriatric patients for hip fracture surgery: does it matter? Osteoporos Int 21:555–572CrossRef
10.
Zurück zum Zitat Ashouri F, Al-Jundi W, Patel A, Mangwani J (2011) Management of warfarin anticoagulation in patients with fractured neck of femur. ISRN Hematol 2011:294628PubMedCentralPubMed Ashouri F, Al-Jundi W, Patel A, Mangwani J (2011) Management of warfarin anticoagulation in patients with fractured neck of femur. ISRN Hematol 2011:294628PubMedCentralPubMed
11.
Zurück zum Zitat Kammerlander C et al (2011) The Tyrolean Geriatric Fracture Center: an orthogeriatric co-management model. Z Gerontol Geriatr 44:363–367PubMedCrossRef Kammerlander C et al (2011) The Tyrolean Geriatric Fracture Center: an orthogeriatric co-management model. Z Gerontol Geriatr 44:363–367PubMedCrossRef
12.
Zurück zum Zitat Cushman M, Lim MW, Zakai FNA (2011) Clinical practice guide on anticoagulant dosing and management of anticoagulant- associated bleeding complications in adults. American College of Chest Physicians Evidence- Based Clinical Practice Guideline on Antithrombotic and Thrombolytic Therapy (8th Edition). 1–8 Cushman M, Lim MW, Zakai FNA (2011) Clinical practice guide on anticoagulant dosing and management of anticoagulant- associated bleeding complications in adults. American College of Chest Physicians Evidence- Based Clinical Practice Guideline on Antithrombotic and Thrombolytic Therapy (8th Edition). 1–8
13.
Zurück zum Zitat Luxembourg B, Krause M, Lindhoff-Last E (2007) Basiswissen Gerinnungslabor. Dtsch Ärztebl 21:1489–1498 Luxembourg B, Krause M, Lindhoff-Last E (2007) Basiswissen Gerinnungslabor. Dtsch Ärztebl 21:1489–1498
14.
Zurück zum Zitat Poort SR, Rosendaal FR, Reitsma PH, Bertina RM (1996) A common genetic variation in the 3’-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88:3698–3703PubMed Poort SR, Rosendaal FR, Reitsma PH, Bertina RM (1996) A common genetic variation in the 3’-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88:3698–3703PubMed
15.
Zurück zum Zitat Jackson CMC, Esnouf MPM, Lindahl TLT (2002) A critical evaluation of the prothrombin time for monitoring oral anticoagulant therapy. Pathophysiol Haemost Thromb 33:43–51CrossRef Jackson CMC, Esnouf MPM, Lindahl TLT (2002) A critical evaluation of the prothrombin time for monitoring oral anticoagulant therapy. Pathophysiol Haemost Thromb 33:43–51CrossRef
17.
Zurück zum Zitat Dager WE, Gosselin RC, Kitchen S, Dwyre D (2012) Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: a multicenter, in vitro study. Ann Pharmacother 46:1627–1636PubMedCrossRef Dager WE, Gosselin RC, Kitchen S, Dwyre D (2012) Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: a multicenter, in vitro study. Ann Pharmacother 46:1627–1636PubMedCrossRef
18.
Zurück zum Zitat Eerenberg ES et al (2011) Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124:1573–1579PubMedCrossRef Eerenberg ES et al (2011) Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124:1573–1579PubMedCrossRef
19.
Zurück zum Zitat Janssen Pharmaceuticals, Inc. XARELTO® [package insert]. janssenmedicalinformation.com at (http://www.janssenmedicalinformation.com/assets/pdf/products/files/Xarelto/pi/ENC-010330-11.pdf) Janssen Pharmaceuticals, Inc. XARELTO® [package insert]. janssenmedicalinformation.com at (http://​www.​janssenmedicalin​formation.​com/​assets/​pdf/​products/​files/​Xarelto/​pi/​ENC-010330-11.​pdf)
20.
Zurück zum Zitat Funk DMA (2012) Coagulation assays and anticoagulant monitoring. Hematology Am Soc Hematol Educ Program 2012:460–465PubMed Funk DMA (2012) Coagulation assays and anticoagulant monitoring. Hematology Am Soc Hematol Educ Program 2012:460–465PubMed
21.
Zurück zum Zitat Eikelboom JWJ, Quinlan DJD, Douketis JDJ (2001) Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 358:7–7CrossRef Eikelboom JWJ, Quinlan DJD, Douketis JDJ (2001) Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 358:7–7CrossRef
22.
Zurück zum Zitat Chassot PG, Delabays A, Spahn DR (2007) Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction. Br J Anaesth 99:316–328PubMedCrossRef Chassot PG, Delabays A, Spahn DR (2007) Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction. Br J Anaesth 99:316–328PubMedCrossRef
23.
Zurück zum Zitat Thaler HW et al (2013) Stressulkusprophylaxe, Thromboseprophylaxe und Gerinnungsmanagement bei Patienten mit Hüftfrakturen. Wien Med Wochenschr. doi:10.1007/s10354-013-0234-0 Thaler HW et al (2013) Stressulkusprophylaxe, Thromboseprophylaxe und Gerinnungsmanagement bei Patienten mit Hüftfrakturen. Wien Med Wochenschr. doi:10.1007/s10354-013-0234-0
24.
Zurück zum Zitat ÖGARI—Österreichische Gesellschaft für Anästhesiologie und Intensivmedizin. Regionalanästhesie unter gerinnungshemmender Medikation. oegari.at (2013). http://www.oegari.at/web_files/dateiarchiv/116/Regionalan%C3%A4sthesie%20und%20Gerinnungshemmer%202013.pdf. Accessed 23 Jan 2014 ÖGARI—Österreichische Gesellschaft für Anästhesiologie und Intensivmedizin. Regionalanästhesie unter gerinnungshemmender Medikation. oegari.at (2013). http://​www.​oegari.​at/​web_​files/​dateiarchiv/​116/​Regionalan%C3%A4sthesie%20und%20Gerinnungshemmer%202013.pdf. Accessed 23 Jan 2014
25.
Zurück zum Zitat Friedman PAP, Rosenberg RDR, Hauschka PVP, Fitz-James AA (1977) A spectrum of partially carboxylated prothrombins in the plasmas of coumarin-treated patients. Biochim Biophys Acta 494:271–276PubMedCrossRef Friedman PAP, Rosenberg RDR, Hauschka PVP, Fitz-James AA (1977) A spectrum of partially carboxylated prothrombins in the plasmas of coumarin-treated patients. Biochim Biophys Acta 494:271–276PubMedCrossRef
26.
Zurück zum Zitat Douketis JD et al (212) Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST 141:e326S–e350S Douketis JD et al (212) Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST 141:e326S–e350S
27.
Zurück zum Zitat Quinlan DJ, Eikelboom JW, Weitz JI (2013) Four-factor prothrombin complex concentrate for urgent reversal of vitamin K antagonists in patients with major bleeding. Circulation 128:1179–1181PubMed Quinlan DJ, Eikelboom JW, Weitz JI (2013) Four-factor prothrombin complex concentrate for urgent reversal of vitamin K antagonists in patients with major bleeding. Circulation 128:1179–1181PubMed
28.
Zurück zum Zitat Department of Surgical Education, Orlando Regional Medical Center (2012) Warfarin Reversal Guideline. 1–8 Department of Surgical Education, Orlando Regional Medical Center (2012) Warfarin Reversal Guideline. 1–8
29.
Zurück zum Zitat Ansell J et al (2008) Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:160S–198SPubMedCrossRef Ansell J et al (2008) Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:160S–198SPubMedCrossRef
30.
Zurück zum Zitat Bonow RO et al (2008) focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. J Am Coll Cardiol 52:e1–e142PubMedCrossRef Bonow RO et al (2008) focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. J Am Coll Cardiol 52:e1–e142PubMedCrossRef
31.
Zurück zum Zitat Smith EB, Parvizi J, Purtill JJ (2011) Delayed surgery for patients with femur and hip fractures—risk of deep venous thrombosis. J Trauma 70:E113–E116PubMedCrossRef Smith EB, Parvizi J, Purtill JJ (2011) Delayed surgery for patients with femur and hip fractures—risk of deep venous thrombosis. J Trauma 70:E113–E116PubMedCrossRef
32.
Zurück zum Zitat Gage BF et al (2001) Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285:2864–2870PubMedCrossRef Gage BF et al (2001) Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285:2864–2870PubMedCrossRef
33.
Zurück zum Zitat Gage BF et al (2004) Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 110:2287–2292PubMedCrossRef Gage BF et al (2004) Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 110:2287–2292PubMedCrossRef
34.
Zurück zum Zitat Keeling D et al (2011) Guidelines on oral anticoagulation with warfarin—fourth edition. Br J Haematol 154:311–324PubMedCrossRef Keeling D et al (2011) Guidelines on oral anticoagulation with warfarin—fourth edition. Br J Haematol 154:311–324PubMedCrossRef
35.
Zurück zum Zitat Jaffer AK, Brotman DJ, Chukwumerije N (2003) When patients on warfarin need surgery. Cleve Clin J Med 70:973–984PubMedCrossRef Jaffer AK, Brotman DJ, Chukwumerije N (2003) When patients on warfarin need surgery. Cleve Clin J Med 70:973–984PubMedCrossRef
36.
Zurück zum Zitat Bhatia M, Talawadekar G, Parihar S, Smith A (2010) An audit of the role of vitamin K in the reversal of International Normalised Ratio (INR) in patients undergoing surgery for hip fracture. Ann R Coll Surg Engl 92:473–476PubMedCentralPubMedCrossRef Bhatia M, Talawadekar G, Parihar S, Smith A (2010) An audit of the role of vitamin K in the reversal of International Normalised Ratio (INR) in patients undergoing surgery for hip fracture. Ann R Coll Surg Engl 92:473–476PubMedCentralPubMedCrossRef
38.
Zurück zum Zitat Rucci P, Claviés M-C, Donat F, Necciari J (2002) Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins. Clin Pharmacokinet 41(Suppl 2):11–18CrossRef Rucci P, Claviés M-C, Donat F, Necciari J (2002) Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins. Clin Pharmacokinet 41(Suppl 2):11–18CrossRef
39.
Zurück zum Zitat Glaxo Group Ltd. Arixtra® Product Information. ema.europa.eu. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000403/WC500027746.pdf. Accessed 23 Jan 2014 Glaxo Group Ltd. Arixtra® Product Information. ema.europa.eu. http://​www.​ema.​europa.​eu/​docs/​en_​GB/​document_​library/​EPAR_​-_​Product_​Information/​human/​000403/​WC500027746.​pdf.​ Accessed 23 Jan 2014
40.
Zurück zum Zitat Boneu B et al (1995) Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/Org31540) with high affinity to antithrombin III in man. Thromb Haemost 74:1468–1473PubMed Boneu B et al (1995) Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/Org31540) with high affinity to antithrombin III in man. Thromb Haemost 74:1468–1473PubMed
41.
Zurück zum Zitat Donat F et al (2002) The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet 41(Suppl 2):1–9PubMedCrossRef Donat F et al (2002) The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet 41(Suppl 2):1–9PubMedCrossRef
42.
Zurück zum Zitat EMA European Medicines Agency. EPAR summary for the public: Arixtra® fondaparinux sodium. ema.europa.eu (2010) http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000403/WC500027736.pdf. Accessed 23 Jan 2014 EMA European Medicines Agency. EPAR summary for the public: Arixtra® fondaparinux sodium. ema.europa.eu (2010) http://​www.​ema.​europa.​eu/​docs/​en_​GB/​document_​library/​EPAR_​-_​Summary_​for_​the_​public/​human/​000403/​WC500027736.​pdf.​ Accessed 23 Jan 2014
43.
Zurück zum Zitat ÖGARI—Österreichische Gesellschaft für Anästhesiologie und Intensivmedizin. Perioperatives ‘Bridging’ der neuen oralen Antikoagulationen. oegari.at (2012) http://www.oegari.at/web_files/dateiarchiv/116/Perioperatives%20Bridging%20der%20Neuen%20Oralen%20Antikoagulantien%202012.pdf. ÖGARI—Österreichische Gesellschaft für Anästhesiologie und Intensivmedizin. Perioperatives ‘Bridging’ der neuen oralen Antikoagulationen. oegari.at (2012) http://​www.​oegari.​at/​web_​files/​dateiarchiv/​116/​Perioperatives%20Bridging%20der%20Neuen%20Oralen%20Antikoagulantien%202012.pdf.
44.
Zurück zum Zitat EMA European Medicines Agency. EPAR summary for the public: Xarelto® rivaroxaban. ema.europa.eu (2013) http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000944/human_med_001155.jsp&mid=WC0b01ac058001d124. Accessed 23 Jan 2014 EMA European Medicines Agency. EPAR summary for the public: Xarelto® rivaroxaban. ema.europa.eu (2013) http://​www.​ema.​europa.​eu/​ema/​index.​jsp?​curl=​pages/​medicines/​human/​medicines/​000944/​human_​med_​001155.​jsp&​mid=​WC0b01ac058001d1​24.​ Accessed 23 Jan 2014
45.
Zurück zum Zitat Kubitza D, Becka M, Wensing G et al (2005) Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 61:873–880PubMedCrossRef Kubitza D, Becka M, Wensing G et al (2005) Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 61:873–880PubMedCrossRef
46.
Zurück zum Zitat Bayer Health Care Manufacturing Srl. Xarelto® EPAR Product information. ema.europa.eu. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf. Accessed 23 Jan 2014 Bayer Health Care Manufacturing Srl. Xarelto® EPAR Product information. ema.europa.eu. http://​www.​ema.​europa.​eu/​docs/​en_​GB/​document_​library/​EPAR_​-_​Product_​Information/​human/​000944/​WC500057108.​pdf.​ Accessed 23 Jan 2014
47.
Zurück zum Zitat ÖGARI—Österreichische Gesellschaft für Anästhesiologie und Intensivmedizin. Gerinnungsmanagement bei traumatisch bedingter Massivblutung. oegari.at (2013) http://www.oegari.at/web_files/dateiarchiv/116/Gerinnungsmanagement%20bei%20traumatisch%20bedingter%20Massivblutung2013.pdf ÖGARI—Österreichische Gesellschaft für Anästhesiologie und Intensivmedizin. Gerinnungsmanagement bei traumatisch bedingter Massivblutung. oegari.at (2013) http://​www.​oegari.​at/​web_​files/​dateiarchiv/​116/​Gerinnungsmanage​ment%20bei%20traumatisch%20bedingter%20Massivblutung2013.pdf
48.
Zurück zum Zitat EMA European Medicines Agency. Pradaxa® EPAR summary for the public. ema.europa.eu (2012) (http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000829/WC500041060.pdf. Accessed 23 Jan 2014 EMA European Medicines Agency. Pradaxa® EPAR summary for the public. ema.europa.eu (2012) (http://​www.​ema.​europa.​eu/​docs/​en_​GB/​document_​library/​EPAR_​-_​Summary_​for_​the_​public/​human/​000829/​WC500041060.​pdf.​ Accessed 23 Jan 2014
49.
Zurück zum Zitat Ridgefield, C.T. Boehringer Ingelheim Pharma GmbH & Co. KG. Dabigatran etexilate (Pradaxa®) for the treatment of atrial fibrillation. package insert Ridgefield, C.T. Boehringer Ingelheim Pharma GmbH & Co. KG. Dabigatran etexilate (Pradaxa®) for the treatment of atrial fibrillation. package insert
50.
Zurück zum Zitat Blech S, Ebner T, Ludwig-Schwellinger E et al (2008) The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 36:386–399PubMedCrossRef Blech S, Ebner T, Ludwig-Schwellinger E et al (2008) The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 36:386–399PubMedCrossRef
51.
Zurück zum Zitat Lehr T et al (2012) Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation. J Clin Pharmacol 52:1373–1378PubMedCrossRef Lehr T et al (2012) Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation. J Clin Pharmacol 52:1373–1378PubMedCrossRef
52.
Zurück zum Zitat Boehringer Ingelheim Pharma GmbH & Co. KG. Pradaxa® EPAR Product Information. ema.europa.eu. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf- Accessed 23 Jan 2014 Boehringer Ingelheim Pharma GmbH & Co. KG. Pradaxa® EPAR Product Information. ema.europa.eu. http://​www.​ema.​europa.​eu/​docs/​en_​GB/​document_​library/​EPAR_​-_​Product_​Information/​human/​000829/​WC500041059.​pdf- Accessed 23 Jan 2014
53.
Zurück zum Zitat Tohgi H, Konno S, Tamura K et al (1992) Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin. Stroke 23:1400–1403PubMedCrossRef Tohgi H, Konno S, Tamura K et al (1992) Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin. Stroke 23:1400–1403PubMedCrossRef
54.
Zurück zum Zitat Raithel M et al (2005) Significance of salicylate intolerance in diseases of the lower gastrointestinal tract. J Physiol Pharmacol 56(Suppl 5):89–102PubMed Raithel M et al (2005) Significance of salicylate intolerance in diseases of the lower gastrointestinal tract. J Physiol Pharmacol 56(Suppl 5):89–102PubMed
55.
Zurück zum Zitat Hawkey CJ, Langman MJS (2003) Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors. Gut 52:600–608PubMedCentralPubMedCrossRef Hawkey CJ, Langman MJS (2003) Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors. Gut 52:600–608PubMedCentralPubMedCrossRef
56.
Zurück zum Zitat Beckerath von NN et al (2005) Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 112:2946–2950 Beckerath von NN et al (2005) Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 112:2946–2950
57.
Zurück zum Zitat Eikelboom JWJ, Hirsh JJ, Spencer FAF et al (2012) Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e89S–e119SPubMedCentralPubMedCrossRef Eikelboom JWJ, Hirsh JJ, Spencer FAF et al (2012) Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e89S–e119SPubMedCentralPubMedCrossRef
58.
Zurück zum Zitat Li CC, Hirsh JJ, Xie CC et al (2012) Reversal of the anti-platelet effects of aspirin and clopidogrel. J Thromb Haemost 10:521–528PubMedCrossRef Li CC, Hirsh JJ, Xie CC et al (2012) Reversal of the anti-platelet effects of aspirin and clopidogrel. J Thromb Haemost 10:521–528PubMedCrossRef
59.
Zurück zum Zitat Gerstein NS, Schulman PM, Gerstein WH et al (2012) Should more patients continue aspirin therapy perioperatively? Clinical impact of aspirin withdrawal syndrome. Ann Surg 255:811–819PubMedCrossRef Gerstein NS, Schulman PM, Gerstein WH et al (2012) Should more patients continue aspirin therapy perioperatively? Clinical impact of aspirin withdrawal syndrome. Ann Surg 255:811–819PubMedCrossRef
60.
Zurück zum Zitat Collet JP et al (2004) Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation 110:2361–2367PubMedCrossRef Collet JP et al (2004) Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation 110:2361–2367PubMedCrossRef
61.
Zurück zum Zitat Iakovou I et al (2005) Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293:2126–2130PubMedCrossRef Iakovou I et al (2005) Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293:2126–2130PubMedCrossRef
62.
Zurück zum Zitat Sharma AK et al (2004) Major noncardiac surgery following coronary stenting: when is it safe to operate? Catheter Cardiovasc Interv 63:141–145PubMedCrossRef Sharma AK et al (2004) Major noncardiac surgery following coronary stenting: when is it safe to operate? Catheter Cardiovasc Interv 63:141–145PubMedCrossRef
63.
Zurück zum Zitat National Institute For Health And Clinical Excellence (2011) The management of hip fracture in adults. 124 (nice.org.uk) National Institute For Health And Clinical Excellence (2011) The management of hip fracture in adults. 124 (nice.org.uk)
64.
Zurück zum Zitat Leonidou A, Rallan R, Cox N et al (2013) Comparison of different warfarin reversal protocols on surgical delay and complication rate in hip fracture patients. J Orthop Surg (Hong Kong) 21:142–145 Leonidou A, Rallan R, Cox N et al (2013) Comparison of different warfarin reversal protocols on surgical delay and complication rate in hip fracture patients. J Orthop Surg (Hong Kong) 21:142–145
Metadaten
Titel
Algorithm for anticoagulation management in geriatric hip fracture patients—Surgeons save Blood
verfasst von
M.A. Wendl-Soeldner
C.W.I. Moll
C. Kammerlander
M. Gosch
T. Roth, MD
Publikationsdatum
01.02.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Zeitschrift für Gerontologie und Geriatrie / Ausgabe 2/2014
Print ISSN: 0948-6704
Elektronische ISSN: 1435-1269
DOI
https://doi.org/10.1007/s00391-013-0595-4

Weitere Artikel der Ausgabe 2/2014

Zeitschrift für Gerontologie und Geriatrie 2/2014 Zur Ausgabe

Beiträge zum Themenschwerpunkt

Perioperative Ernährungstherapie

Mitteilungen der DGG

Mitteilungen der DGG